logo
Sign in

INVIZYNE TECHNOLOGIES INC

Monrovia, CA · Clean tech · Public

Cell-free enzymatic bioreactors for converting biomass into renewable fuels and chemicals

Claim this profile

Follows are private to you and power your alerts

Updated · exozymes.com

Sector
Clean tech
Headquarters
Monrovia, CA
Latest Form D
$12K, Nov 2024
Total capital
$8.6M
Federal grants
$8.6M
16 awards · 2019–2026
Rank in peer group#6 of 23
Private capital raised
$12K
1 Form D · last Nov 2024
23 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
2
16 pending · first 2022
Rank in peer group#10 of 23

Capital timeline

20192020202120222023202420252026FEDERAL ↑EQUITY ↓Cumulative $8.6M$1.1M$650K$2.1M$1.1M$647K$1M1st Form D$12K
2019202120232025FEDERAL ↑EQUITY ↓Cumulative $8.6M$1.1M$2.1M$1.1M$1M1st Form D$12K

Latest events

  • Federal grantHealth and Human S · Phase II · SimplePath IIB: Pre-clinical development of Cannabinoid analogs$1M
  • Federal grantHealth and Human S · Phase I · Bio-Click: A cell-free high-throughput platform for the engineering of enzymatic group transfer reactions$284K
  • Private capital raisedForm D · SEC · 1st filing$12K
  • Federal grantHealth and Human S · Phase I · GlyCoSAM: Glycolysis coupled S-adenosyl methionine regeneration for cell-free methylation reactions$244K
  • Federal grantHealth and Human S · Phase II · SimplePath II: A Cell-free Enzymatic Platform for Cannabinoid Biosynthesis$48K
  • Federal grantHealth and Human S · Phase II · SimplePath II: A Cell-free Enzymatic Platform for Cannabinoid Biosynthesis$631K
  • Federal grantHealth and Human S · Phase II · SimplePath II: A Cell-free Enzymatic Platform for Cannabinoid Biosynthesis$7K
Show 10 earlier federal awards
  • Federal grantHealth and Human S · Phase II · SimplePath II: A Cell-free Enzymatic Platform for Cannabinoid Biosynthesis$647K
  • Federal grantEnergy · Phase II · Cell-Free Production of Terpenoid Chemical Astaxanthin Using Crude Cofactor Lysates$1.1M
  • Federal grantEnergy · Phase I · Simplifying Reactor Setup for Cell-Free Biofuel Production$246K
  • Federal grantHealth and Human S · Phase II · SimplePath II: A Cell-free Enzymatic Platform for Cannabinoid Biosynthesis$2.1M
  • Federal grantHealth and Human S · Phase II · SimplePath II: A Cell-free Enzymatic Platform for Cannabinoid Biosynthesis$72K
  • Federal grantHealth and Human S · Phase II · SimplePath II: A Cell-free Enzymatic Platform for Cannabinoid Biosynthesis$650K
  • Federal grantEnergy · Phase II · Cell-Free Production of Terpenoid Chemical Astaxanthin Using Crude Cofactor Lysates$1.1M
  • Federal grantHealth and Human S · Phase I · SimplePath: A Cell-free Enzymatic Platform for Cannabinoid Boisynthesis$150K
  • Federal grantHealth and Human S · Phase I · SimplePath: A Cell-free Enzymatic Platform for Cannabinoid Boisynthesis$150K
  • Federal grantEnergy · Phase I · Cell-Free Production of Terpenoid Chemicals and fules$200K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

65months

from INVIZYNE TECHNOLOGIES INC’s first federal award to its first private round.

First federal award · Jul 2019
Energy · $200K
First Form D · Nov 2024
$12K · 1st Form D
Awards before first raise
14 awards

An association in public records, not a cause or a prediction.

Standing among 23 peers

Line = median

Clean tech · System

  • Federal grants#6 · top 26%
  • Granted patents#10 · top 43%
  • Linked publications#2 · top 9%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Anthony DiGiandomenicoDirectorNamed in SEC Form D filings
  • Christopher MarlettDirectorNamed in SEC Form D filings
  • James BowieDirectorNamed in SEC Form D filings
  • James LalondeDirectorNamed in SEC Form D filings
  • Lon BellDirectorNamed in SEC Form D filings
  • Michael HeltzenExecutive OfficerNamed in SEC Form D filings
Show all 7 people
  • Mohammad HayatExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

USPTO · 2 granted of 18
  • PendingRecombinant Polypeptides With Berberine Bridge Enzyme Activity Useful For The Biosynthesis Of CannabinoidsUSPTOApplication 18726859
  • PendingBiosynthesis Of Cyclolavandulyl Derivatives Of Aromatic CompoundsUSPTOApplication 18918626
  • GrantedPrenyltransferase Variants With Increased ThermostabilityUSPTOUS 12,084,689
Show all 18 patent records
  • Recombinant Polypeptides With Berberine Bridge Enzyme Activity Useful For The Biosynthesis Of CannabinoidsJun 12, 2025 · Application 18726859Pending
  • Biosynthesis Of Cyclolavandulyl Derivatives Of Aromatic CompoundsFeb 6, 2025 · Application 18918626Pending
  • Prenyltransferase Variants With Increased ThermostabilitySep 10, 2024 · US 12,084,689Granted
  • Biosynthesis Of Substituted Compounds And CannabinoidsMar 7, 2024 · Application 18227719Pending
  • Prenyltransferase Variants With Increased ThermostabilityDec 6, 2022 · US 11,518,983Granted
  • Biosynthesis Of Cyclolavandulyl Derivatives Of Aromatic CompoundsApplication PCTUS2023019381Pending
  • Recombinant Polypeptides With Berberine Bridge Enzyme Activity Useful For The Biosynthesis Of CannabinoidsApplication PCTUS2023060204Pending
  • Biosynthesis Of Substituted Compounds And CannabinoidsApplication 63370070Pending
  • Prenyltransferase Variants With Increased ThermostabilityApplication PCTUS2022030816Pending
  • Biosynthesis Of Cyclolavandulyl Derivatives Of Aromatic CompoundsApplication 63333670Pending
  • Recombinant Polypeptides With Berberine Bridge Enzyme Activity Useful For The Biosynthesis Of CannabinoidsApplication 63297561Pending
  • Prenyltransferase Variants With Increased ThermostabilityApplication 63193221Pending
  • In Vitro Synthesis Of Coenzyme A And Acetyl-coa For Cell-free BiocatalysisApplication PCTUS2025016740Pending
  • In Situ Nadp Biosynthesis Process For Biobased Chemical ProductionApplication 19487208Pending
  • In Situ Nadp Biosynthesis Process For Biobased Chemical ProductionApplication PCTUS2024031044Pending
  • In Vitro Synthesis of Coenzyme A and Acetyl-CoA for Cell-Free BiocatalysisApplication 63556767Pending
  • Biosynthesis Of Substituted Compounds And CannabinoidsApplication PCTUS2023071340Pending
  • In Situ Nadp Biosynthesis Process For Biobased Chemical ProductionApplication 63468911Pending

Recent research by its founders

  • Exozymes for Biomanufacturing: Toward Clarity and Precision in the Cell-Free Space20252 cites
  • Thermostable Enzyme Variants in the Lower Mevalonate Pathway Improve Isoprenoid Production by Cell-Free Biocatalysis20251 cites
  • Synthetic Biochemistry: The Bio-inspired Cell-Free Approach to Commodity Chemical Production2020141 cites

Related companies, and why

Regulatory activity · Clean tech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .